Exelixis (EXEL) Capital Expenditures (2010 - 2026)
Exelixis' (EXEL) quarterly Capital Expenditures came in at $1.5 million in Q2 2026, down 48.88% year-on-year from $3.0 million in Q2 2025, and up 30.42% quarter-over-quarter from $1.2 million in Q1 2026.
Exelixis (EXEL) Capital Expenditures (2010 - 2026) Analysis & Trends
Exelixis' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.5 million for Q2 2026.
- On a quarterly basis, Capital Expenditures fell 48.88% year-over-year to $1.5 million in Q2 2026; TTM through Apr 2026 was $7.0 million, a 67.8% decrease from a year earlier, with the FY2026 full-year figure at $8.4 million, down 70.36% from the prior year.
- Capital Expenditures advanced to $1.5 million in Q2 2026 per EXEL's latest filing, from $1.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $13.1 million in Q4 2023 and bottomed at $1.2 million in Q1 2026.
- The 5-year median for Capital Expenditures is $5.9 million (2023), against an average of $6.3 million.
- Across the five-year window, Capital Expenditures surged 117.62% in 2022 and sank 81.92% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $9.7 million in 2022, then soared by 35.18% to $13.1 million in 2023, then plunged by 37.59% to $8.2 million in 2024, then sank by 81.92% to $1.5 million in 2025, then gained by 1.82% to $1.5 million in 2026.
- Per Business Quant, the three latest EXEL Capital Expenditures figures stand at $1.5 million (Q2 2026), $1.2 million (Q1 2026), and $1.5 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 1.51 Mn |
| Apr 3, 2026 | 1.51 Mn |
| Jan 2, 2026 | 1.16 Mn |
| Jan 2, 2026 | 1.16 Mn |
| Oct 3, 2025 | 1.48 Mn |
| Oct 3, 2025 | 1.48 Mn |
| Jul 4, 2025 | 2.84 Mn |
| Jul 4, 2025 | 2.84 Mn |
| Apr 4, 2025 | 2.95 Mn |
| Apr 4, 2025 | 2.95 Mn |
| Jan 3, 2025 | 3.98 Mn |
| Jan 3, 2025 | 3.98 Mn |
| Sep 27, 2024 | 8.20 Mn |
| Sep 27, 2024 | 8.20 Mn |
| Jun 28, 2024 | 6.57 Mn |
| Jun 28, 2024 | 6.57 Mn |
| Mar 29, 2024 | 9.69 Mn |
| Mar 29, 2024 | 9.69 Mn |
| Dec 29, 2023 | 13.14 Mn |
| Dec 29, 2023 | 13.14 Mn |